Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 13,334 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Janux Therapeutics Trading Up 1.3 %

NASDAQ JANX traded up $0.68 during trading on Friday, hitting $53.92. The company had a trading volume of 662,337 shares, compared to its average volume of 802,119. The company's fifty day moving average is $54.53 and its 200-day moving average is $47.83. Janux Therapeutics, Inc. has a one year low of $7.79 and a one year high of $71.71. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -46.09 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business's revenue was down 82.6% compared to the same quarter last year. As a group, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in JANX. Janus Henderson Group PLC boosted its holdings in Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company's stock worth $114,587,000 after acquiring an additional 721,563 shares in the last quarter. Logos Global Management LP raised its stake in Janux Therapeutics by 400.0% during the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company's stock valued at $31,418,000 after buying an additional 600,000 shares during the last quarter. Point72 Asset Management L.P. increased its position in Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company's stock valued at $17,985,000 after acquiring an additional 259,445 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock worth $10,639,000 after purchasing an additional 156,675 shares during the period. Finally, Barclays PLC raised its position in Janux Therapeutics by 496.5% in the third quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after acquiring an additional 144,883 shares during the period. Institutional investors own 75.39% of the company's stock.

Wall Street Analyst Weigh In

JANX has been the topic of a number of analyst reports. Scotiabank boosted their target price on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a report on Wednesday, December 4th. UBS Group initiated coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a "buy" rating and a $69.00 price target for the company. Leerink Partnrs upgraded Janux Therapeutics to a "strong-buy" rating in a research report on Friday, November 22nd. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. Finally, BTIG Research boosted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.